THNR

Amplify Weight Loss Drug & Treatment ETF

$25.02
+0.00%
Market closed. Last update: 10:55 PM ET

📎 Investment Objective

The Amplify Weight Loss Drug & Treatment ETF (THNR) seeks to provide investment results that, before fees and expenses, correspond generally to the performance of the Indxx Weight Loss Drug & Treatment Index.

Overview

ETF tracking Amplify Weight Loss Drug & Treatment ETF

Category Healthcare
Issuer Other
Inception Date 2024-05-21
Market Cap $3.3M
Average Volume N/A
Dividend Yield 0.88%
52-Week Range $18.85 - $24.96
VWAP $24.99

Performance

Loading performance data...

Price Chart

Investment Summary

📎 Investment Objective

The Amplify Weight Loss Drug & Treatment ETF (THNR) seeks to provide investment results that, before fees and expenses, correspond generally to the performance of the Indxx Weight Loss Drug & Treatment Index.

🎯 Investment Strategy

The fund invests at least 80% of its total assets in the securities that comprise the Indxx Weight Loss Drug & Treatment Index. The index tracks the performance of companies involved in the development, production, and distribution of weight loss drugs and treatments.

✨ Key Features

  • Focuses on companies in the weight loss drug and treatment industry
  • Passively managed to track the Indxx Weight Loss Drug & Treatment Index
  • Low expense ratio of 0.00%
  • Relatively new fund with no performance history

⚠️ Primary Risks

  • Concentration risk as the fund is focused on a specific industry
  • Lack of performance history makes it difficult to evaluate
  • Potential volatility due to the specialized nature of the underlying companies
  • Low assets under management may impact liquidity

👤 Best For

This ETF may be suitable for investors with a higher risk tolerance who are seeking exposure to the weight loss drug and treatment industry as part of a diversified portfolio. However, the lack of performance history means it may not be appropriate for more conservative investors.